Find the Perfect Plan for Your Investment Journey
F
Latest price
52 Week Range
€15.14 - €20.35
Next Earnings Date
-
Next Earnings Date
-
Latest price
Market Cap | €1.41B |
EV | €1.68B |
Shares Outstanding | 72.86M |
Beta | 0.25 |
Analyst Rating | BUY |
Analyst Target Price | €23.04 |
P/E 2025E | 14.15x |
P/Revenue 2025E | 1.47x |
Revenue | 15.00% |
EPS | 10.30% |
Operating Cash Flow | 11.90% |
Free Cash Flow | 6.20% |
Revenue | 7.60% |
EPS | 14.00% |
Operating Cash Flow | 17.00% |
Free Cash Flow | 22.10% |
Gross Margin 2025E | 62.60% |
Net Profit Margin 2025E | 10.51% |
ROE 2025E | 18.80% |
ROCE 2024 | 16.69% |
DPS 2025E | €0.36 |
Payout Ratio 2025E | 26.67% |
Div. Yield 2025E | 1.87% |
DPS Last 3Y CAGR | 20.50% |
Price
%
1M
3M
6M
1Y
3Y
5Y
F
Fagron NV
FAGR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Padilla, Rafael
Employees
3,828
Website
www.fagron.comIPO Date
2007-10-05
Headquarters
Venecoweg 20A, Nazareth, East Flanders, 9810, Belgium
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved